Future oncology (London, England)HumansAntibodiesMonoclonalHumanizedCarcinoma
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.
Kenneth O'Byrne, Emilio Esteban, Cheen Leng Lee, Alinta Hegmane, Constantin Volovat, Giuseppe Lo Russo, Dimitrios Ziogas, Akin Atmaca, Martin Sebastian, Margarita Majem
Published: 202510.1080/14796694.2025.2597404
Abstract
BACKGROUND: Although immune checkpoint inhibitors (ICIs) form the cornerstone of first-line treatment for non-small cell lung cancer (NSCLC), the challenge remains to improve patients' long-term outcomes. Eftilagimod alfa (efti) activates antigen-pre…
Preview only. Read the full abstract at the source